Real-world Study on the Efficacy,Safety and Economics of Vancomycin Hydrochloride for Injection from Two Manufacturers
10.3870/j.issn.1004-0781.2023.12.018
- VernacularTitle:两个厂家注射用盐酸万古霉素有效性和安全性及经济性的真实世界研究
- Author:
Haixia ZHANG
1
,
2
;
Xingkai CHEN
;
Pei LIANG
;
Jinchun LIU
;
Yichen LI
;
Mengying LIU
;
Siliang WANG
;
Huaijun ZHU
;
Weihong GE
Author Information
1. 南京大学医学院附属鼓楼医院药学部,南京 210008
2. 南京临床药学中心,南京 210008
- Keywords:
Vancomycin;
Real-world study;
Consistency evaluation;
Propensity score matching method
- From:
Herald of Medicine
2023;42(12):1850-1855
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the differences in efficacy,safety and economics of vancomycin hydrochloride for injection between two manufacturers based on real-world data.Methods A total of 6 757 cases of intravenous use of vancomycin hydrochloride for injection from different manufacturers between January 1,2013 and December 31,2019 in the Affiliated Drum Tower Hospital of Nanjing University Medical School were retrospectively analyzed,and 5308 cases were matched by 1∶1 propensity score method,including 2 654 cases in the group A(domestic drug group)and 2 654 cases in group B(the innovator drug group).The differences in efficacy and safety between the two groups were compared.Cost-effectiveness analysis was used to compare the drug economics of the two groups.Results There were no significant differences in clinical cure rate,bacterial clearance rate,and incidence of adverse events between the two groups(P>0.05).In terms of economics,the average cost of vancomycin per capita,average daily cost of vancomycin and average cost of antibiotics per capita were significantly different between the two groups(P<0.05),and the cost of group B was higher than that of group A.Conclusion The efficacy and safety of vancomycin hydrochloride for injection were consistent between the two manufacturers.
